Charles, Edgar D.

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 550

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity

Fibroblast Growth Factor ResearchLiver Disease Diagnosis and Treatment

Cited by 257

BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial

Lawitz, E. J., Shevell, D. E., Tirucherai, G. S., Du, S., Chen, W., Kavita, U., Coste, A., Poordad, F., Karsdal, M., Nielsen, M., et al. (2022) · Hepatology

Liver physiology and pathologyHepatitis C virus research

Cited by 107

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 87

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis

Luo, Y., Oseini, A., Gagnon, R., Charles, E. D., Sidik, K., Vincent, R., Collen, R., Idowu, M., Contos, M. J., Mirshahi, F., et al. (2018) · Scientific Reports

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 74

Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 59

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis

Martin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 45